A review of the use of histrelin acetate in the treatment of prostate cancer.
Crawford
E David
ED
University of Colorado Health Science Center, Aurora, CO 80045, USA. david.crawford@ucdenver.edu
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004343:Drug Implants; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D004343:Drug Implants; D007987:Gonadotropin-Releasing Hormone; C029256:histrelin